Ambrosia Biosciences is a drug discovery company focused on developing orally delivered, small molecule therapies for obesity and metabolic disorders. The company utilizes integrated structural biology, biophysical assays, and AI-powered molecular design to target Class B GPCRs. Its pipeline includes differentiated candidates targeting GLP-1R, GIPR, and Amylin receptors for improved patient outcomes.
Funding
$25M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MKFounders
Product
Problem
Obesity and metabolic disorders pose significant health challenges, often requiring complex and costly interventions. Current treatments may have limitations in efficacy, delivery methods, or patient compliance, creating a need for more accessible and effective therapeutic options.
Solution
Ambrosia Biosciences is developing orally delivered, small molecule therapies designed to address obesity and other metabolic disorders. By focusing on small molecule drugs, Ambrosia aims to create treatments that are both safe and effective, with the convenience of oral administration to improve patient adherence. The company leverages advanced drug discovery techniques to identify and develop best-in-class therapeutics that can transform the lives of individuals affected by these conditions.
Target Audience
The primary target audience includes individuals affected by obesity and metabolic disorders, as well as healthcare providers seeking more effective and accessible treatment options.
Features
- Orally delivered small molecule therapeutics for improved patient compliance.
- Focus on obesity and other metabolic disorders.
- Utilizes advanced drug discovery techniques.
- Aims to develop safe, effective, and affordable treatments.